Evidence map›Paper›PMID 38873056›Full record

ArticleChemical science2024

Organocatalytic diastereo- and atropo-selective construction of eight-membered bridged (hetero)biaryls

Yue Wang, Yue Huang, Xiaoze Bao, Xingfu Wei, Shiqiang Wei, Jingping Qu, Baomin Wang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Chemical science, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Yue WangDepartment of Pharmaceutical Engineering, State Key Laboratory of Fine Chemicals, School of Chemical Engineering, Dalian University of Technology Dalian 116024 P. R. China bmwang@dlut.edu.cn.
Yue HuangDepartment of Pharmaceutical Engineering, State Key Laboratory of Fine Chemicals, School of Chemical Engineering, Dalian University of Technology Dalian 116024 P. R. China bmwang@dlut.edu.cn.
Xiaoze BaoCollege of Pharmaceutical Science & Collaborative Innovation Center of Yangtze River Delta Region Green Pharmaceuticals, Zhejiang University of Technology Hangzhou 310014 P. R. China.ORCID https://orcid.org/0000-0003-3682-2674
Xingfu WeiDepartment of Pharmaceutical Engineering, State Key Laboratory of Fine Chemicals, School of Chemical Engineering, Dalian University of Technology Dalian 116024 P. R. China bmwang@dlut.edu.cn.
Shiqiang WeiDepartment of Pharmaceutical Engineering, State Key Laboratory of Fine Chemicals, School of Chemical Engineering, Dalian University of Technology Dalian 116024 P. R. China bmwang@dlut.edu.cn.
Jingping QuDepartment of Pharmaceutical Engineering, State Key Laboratory of Fine Chemicals, School of Chemical Engineering, Dalian University of Technology Dalian 116024 P. R. China bmwang@dlut.edu.cn.ORCID https://orcid.org/0000-0002-7576-0798
Baomin WangDepartment of Pharmaceutical Engineering, State Key Laboratory of Fine Chemicals, School of Chemical Engineering, Dalian University of Technology Dalian 116024 P. R. China bmwang@dlut.edu.cn.ORCID https://orcid.org/0000-0001-9058-4983

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

An unprecedented and straightforward route for the asymmetric construction of privileged atroposelective bridged (hetero)biaryl eight-membered scaffolds has been accomplished through chiral phosphoric acid catalyzed asymmetric intramolecular [3 + 2] cycloaddition of innovative (hetero)biaryl aldehydes with 3-aminooxindole hydrochlorides. A class of eight-membered bridged (hetero)biaryl lactones fused to spiro[pyrrolidine-oxindole] derivatives, possessing both chiral C-C/C-N axes and multiple contiguous stereocenters, were obtained in good yields with excellent enantioselectivities and diastereoselectivities in one step through this direct strategy. In addition, the good scalability and derivatization of the title compounds demonstrated their synthetic utility.

Identifiers

PMID38873056
PMCPMC11168085

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.